Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. (LUPER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04358237

Recruitment Status : Active, not recruiting

First Posted : April 24, 2020

Last Update Posted : February 2, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

MedSIR

PharmaMar

Merck Sharp & Dohme LLC

Information provided by (Responsible Party):

Antonio Calles Blanco, Blanco, Dr Antonio Calles MD

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	September 30, 2023
Estimated Study Completion Date :	February 20, 2024

To Top